Stockreport
Evolus Q4 Earnings Call Highlights [Yahoo! Finance]
Last evolus, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: us.evolis.com/investor-relations
a “performance beauty” strategy centered on cash-pay aesthetics, practice partnerships, and an expanding injectable portfolio. Strategy update: “beauty-first” positioning and practice partnerships Chief Executive Officer David Moatazedi said Evolus is “redefining the category through a beauty-first lens,” positioning itself as the first company with a neurotoxin dedicated exclusively to cash-based aesthetics rather than reimbursement-driven markets. Moatazedi highlighted practice-focused initiatives intended to drive share gains and retention, including: Evolus , described as the first industry program that rewards practices with co-branded media investment tied to purchase volumes. Evolus Rewards , an SMS-based loyalty program co-branded with clinics, which the company said has grown to more than 1.4 million treated patients over six years. A new portfolio growth rebate , piloted in the fourth quarter and officially launched in January, aimed at rewarding practices for expa
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | EOLS | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
EOLS alerts
EOLS alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
EOLS alerts
High impacting Evolus, Inc. news events
Weekly update
A roundup of the hottest topics
EOLS
NEWS
NEWS
- AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting [Yahoo! Finance][Yahoo! Finance]
- Evolus, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance][Yahoo! Finance]
- Evolus (EOLS) had its "buy" rating reaffirmed by BTIG Research. They now have a $13.00 price target on the stock.[MarketBeat]
- Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript [Seeking Alpha][Seeking Alpha]
- Evolus outlines 2026 revenue guidance of $327M–$337M while expanding international presence and product portfolio [Seeking Alpha][Seeking Alpha]
- More
EOLS
SEC Filings
SEC Filings
- 3/3/26 - Form S-8
- 3/3/26 - Form 10-K
- 3/3/26 - Form 8-K
- EOLS's page on the SEC website
- More